Abstract:Background: NOD-like receptor protein 3 (NLRP3) inflammasome activation is indispensable for atherogenesis. Mitophagy has emerged as a potential strategy to counteract NLRP3 inflammasome activation triggered by impaired mitochondria. Our previous research has indicated that dihydromyricetin, a natural flavonoid, can mitigate NLRP3-mediated endothelial inflammation, suggesting its potential to treat atherosclerosis. However, the precise underlying mechanisms remain elusive. This study sought to investigate whether dihydromyricetin modulates endothelial mitophagy and inhibits NLRP3 inflammasome activation to alleviate atherogenesis, along with the specific mechanisms involved. Methods: Apolipoprotein E-deficient mice on a high-fat diet were administered daily oral gavages of dihydromyricetin for 14 weeks. Blood samples were procured to determine the serum lipid profiles and quantify proinflammatory cytokine concentrations. Aortas were harvested to evaluate atherosclerotic plaque formation and NLRP3 inflammasome activation. Concurrently, in human umbilical vein endothelial cells, Western blotting, flow cytometry, and quantitative real-time PCR were employed to elucidate the mechanistic role of mitophagy in the modulation of NLRP3 inflammasome activation by dihydromyricetin. Results: Dihydromyricetin administration significantly attenuated NLRP3 inflammasome activation and vascular inflammation in mice on a high-fat diet, thereby exerting a pronounced inhibitory effect on atherogenesis. Both in vivo and in vitro, dihydromyricetin treatment markedly enhanced mitophagy. This enhancement in mitophagy ameliorated the mitochondrial damage instigated by saturated fatty acids, thereby inhibiting the activation and nuclear translocation of NF-κB. Consequently, concomitant reductions in the transcript levels of NLRP3 and interleukin-1β (IL-1β), alongside decreased activation of NLRP3 inflammasome and IL-1β secretion, were discerned. Notably, the inhibitory effects of dihydromyricetin on the activation of NF-κB and subsequently the NLRP3 inflammasome were determined to be, at least in part, contingent upon its capacity to promote mitophagy. Conclusion: This study suggested that dihydromyricetin may function as a modulator to promote mitophagy, which in turn mitigates NF-κB activity and subsequent NLRP3 inflammasome activation, thereby conferring protection against atherosclerosis.

Lactucopicrin Inhibits Cytoplasmic Dynein‐Mediated NF‐κB Activation in Inflammated Macrophages and Alleviates Atherogenesis in Apolipoprotein E‐Deficient Mice

Terpene Lactucopicrin Limits Macrophage Foam Cell Formation by a Reduction of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Lipid Rafts

Lactucopicrin promotes fatty acid β-oxidation and attenuates lipid accumulation through adenosine monophosphate-activated protein kinase activation in free fatty acid-induced human hepatoblastoma cancer cells

Anti-Inflammatory Effects of Licania macrocarpa Cuatrec Methanol Extract Target Src- and TAK1-Mediated Pathways

Apigenin Inhibits Macrophage Pyroptosis Through Regulation of Oxidative Stress and the NF-B Pathway and Ameliorates Atherosclerosis

The natural sesquiterpene lactone inulicin suppresses the production of pro-inflammatory mediators via inhibiting NF-κB and AP-1 pathways in LPS-activated macrophages

Kuwanon G Attenuates Atherosclerosis by Upregulation of LXRα-ABCA1/ABCG1 and Inhibition of NFκB Activity in Macrophages

Tanshinone II-A Inhibited Oxidized Low-Density-Lipoprotein Induced LOX-1 Expression in Murine Macrophages by Reduction of Intracellular Reactive Oxygen Species (ROS) and NF-KappaB Activation

Abstract: P1122 EFFECTS OF MACROPHAGE ABCA7 DEFICIENCY ON LIPID METABOLISM AND THE DEVELOPMENT OF ATHEROSCLEROSIS IN LDL RECEPTOR KNOCKOUT MICE

Targeting Macrophage Liver X Receptors by Hydrogel‐encapsulated T0901317 Reduces Atherosclerosis Without Effect on Hepatic Lipogenesis

Natto consumption suppresses atherosclerotic plaque progression in LDL receptor-deficient mice transplanted with iRFP-expressing hematopoietic cells

The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages

Epigallocatechin-3-Gallate Inhibits Matrix Metalloproteinase-9 and Monocyte Chemotactic Protein-1 Expression Through the 67-Κda Laminin Receptor and the TLR4/MAPK/NF-κB Signalling Pathway in Lipopolysaccharide-Induced Macrophages

Anti-inflammatory Effects of Chicanine on Murine Macrophage by Down-Regulating LPS-induced Inflammatory Cytokines in IκBα/MAPK/ERK Signaling Pathways.

Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway

Lipoicmethylenedioxyphenol Reduces Experimental Atherosclerosis Through Activation Of Nrf2 Signaling

Lactobacillus Acidophilus ATCC 4356 Attenuates the Atherosclerotic Progression Through Modulation of Oxidative Stress and Inflammatory Process.

LXR Agonist T0901317′s Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice

A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice.

Tanshinone II-A Inhibits Oxidized LDL-induced LOX-1 Expression in Macrophages by Reducing Intracellular Superoxide Radical Generation and NF-κB Activation

Dihydromyricetin suppresses endothelial NLRP3 inflammasome activation and attenuates atherogenesis by promoting mitophagy